deltatrials
Unknown PHASE2 NCT00002487

Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer

INTRAPERITONEAL METHOTREXATE AND DIPYRIDAMOLE AS SALVAGE TREATMENT FOR ADVANCED OVARIAN CARCINOMA

Sponsor: Ottawa Regional Cancer Centre

Conditions Ovarian Cancer
Interventions dipyridamole methotrexate
Updated 5 times since 2017 Last updated: Sep 16, 2013 Started: Jul 31, 1991

This PHASE2 trial investigates Ovarian Cancer and is currently ongoing. Ottawa Regional Cancer Centre leads this study, which shows 5 recorded versions since 1991 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Jul 1991

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ottawa Regional Cancer Centre
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Ottawa, Canada